Advances in Cancer Research

Advances in Cancer Research

Buch | Hardcover
330 Seiten
2023
Academic Press Inc (Verlag)
978-0-443-19280-7 (ISBN)
148,35 inkl. MwSt
Advances in Cancer Research, Volume 160, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research, with this updated edition covering PFKP: More Than Phosphofructokinase, Setting sail: maneuvering SHP2 activity and its effects in cancer, Mechanical factors driving cancer progression, Microsomal Glutathione Transferase 1 in Cancer and the Regulation of Ferroptosis, Lnc-ing epigenetic mechanisms with autophagy and cancer drug resistance, Head and Neck Cancer Treatment in the Era of Molecular Medicine, Applications of Tissue-Specific and Cancer-Selective Gene Promoters for Cancer Diagnosis and Therapy, and more.

Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018). Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USAThe Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.

1. PFKP: More Than Phosphofructokinase Haizhen Wang, Tiffany Penaloza, Amanda J. Manea, Xueliang Gao 2. Setting sail: maneuvering SHP2 activity and its effects in cancer Colin L. Welsh, Sarah Allen, and Lalima K. Madan 3. Mechanical factors driving cancer progression Jessanne Y Lichtenberg, Sydnie Tran, Priscilla Y Hwang 4. Microsomal Glutathione Transferase 1 in Cancer and the Regulation of Ferroptosis Jie Zhang, Zhi-wei Ye, Ralf Morgenstern, Danyelle M. Townsend, and Kenneth D. Tew 5. Lnc-ing epigenetic mechanisms with autophagy and cancer drug resistance Sandhik Nandi, Atanu Mondal, Aritra Ghosh, Shravanti Mukherjee and Chandrima Das 6. Head and Neck Cancer Treatment in the Era of Molecular Medicine Subramanya Pandruvada, Remi Kessler, and Ann Thai 7. Applications of Tissue-Specific and Cancer-Selective Gene Promoters for Cancer Diagnosis and Therapy Amit Kumar, Swadesh K. Das, Luni Emdad and Paul B. Fisher

Erscheinungsdatum
Reihe/Serie Advances in Cancer Research
Mitarbeit Herausgeber (Serie): Paul B. Fisher, Kenneth D. Tew
Verlagsort San Diego
Sprache englisch
Maße 152 x 229 mm
Gewicht 660 g
Themenwelt Studium Querschnittsbereiche Infektiologie / Immunologie
Naturwissenschaften Biologie Genetik / Molekularbiologie
Naturwissenschaften Biologie Zellbiologie
ISBN-10 0-443-19280-4 / 0443192804
ISBN-13 978-0-443-19280-7 / 9780443192807
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich

von Oliver Schmetzer

Buch | Softcover (2023)
Urban & Fischer in Elsevier (Verlag)
27,00